Loading
Vepugratinib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.
Vepugratinib is a small-molecule drug developed by Eli Lilly and. The sponsor describes its target as FGFR3, which OnCo does not yet have a target page for. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07218380 (A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract), in bladder & urothelial cancer. The largest, NCT07218380, plans to enrol 450 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Vepugratinib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Vepugratinib" OR ABSTRACT:"Vepugratinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vepugratinib, not a curated reading list.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.